Just 16% of Japanese people use lifestyle improving drugs, says DMLI survey

2 August 2001

Although a relatively high percentage of Japanese citizens are aware oflifestyle improving drugs, very few actually use them, according to a study by the Life Design Institute, a think-tank at Dai-ichi Mutual Life Insurance, reported by Pharma Japan.

According to a nationwide questionnaire survey of 600 men and women aged 20 to 69, 86% were aware of hair restorers, 74% of erectile dysfunction drugs, 74% of low-dose contraceptive pills and 48% of anti-obesity drugs and antidepressants. However, only 16.4% of respondents were found to use these drugs. The awareness rate was relatively low for drugs for urinary incontinence (16%), osteoporosis (34%) and smoking cessation aids (37%). Over 90% supported the use of drugs for osteoporosis and urinary incontinence, while 80% did so for hair restorers and smoking cessation, but only 55% favored the use of anti-obesity drugs.

When respondents were asked to list drugs which they personally want to use, the highest percentage listed drugs for osteoporosis (80%), following by those for urinary incontinence (76%), hair restorers (60%), antidepressants (57%), drugs for ED (50% of men) and smoking cessation (48%). The majority of respondents also said that they believed that these lifestyle-improving drugs should be reimbursed under Japan's health insurance programs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight